SCHEMBL5701299

SCHEMBL5701299

CC(CCNC1CCCCC1)Oc1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.49
EPHX1 P07099 1/20 0.49
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 2/20 0.44
CYP2D6 P10635 2/20 0.44
LMNA P02545 1/20 0.44
SCN1A P35498 1/20 0.44
SCN2A Q99250 1/20 0.44
SCN3A Q9NY46 1/20 0.44
MCHR1 Q99705 2/20 0.43
CYP2C19 P33261 1/20 0.41
RAB9A P51151 3/20 0.41
ABL1 P00519 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HPGD P15428 2/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5701229 0.77 KDM4E (0.60) FAAHEPHX1KDM4EALDH1A1CYP1A2
SCHEMBL5701158 0.76 KDM4E (0.61) FAAHEPHX1KDM4EALDH1A1CYP1A2
SCHEMBL5701136 0.75 KDM4E (0.56) FAAHEPHX1KDM4EALDH1A1CYP1A2
SCHEMBL5079349 0.74 SLC6A4 (0.51) FAAHEPHX1RAB9AL3MBTL1HPGD
SCHEMBL10932816 0.71 PPARG (0.49) KDM4ECYP1A2RAB9ANPC1SMN1; SMN2
SCHEMBL9872355 0.70 CYP1A2 (0.52) KDM4ECYP1A2RAB9ANPC1
SCHEMBL18473589 0.70 PPARG (0.55) CYP1A2LMNACYP2C19RAB9ANPC1
SCHEMBL5701307 0.70 CETP (0.46) EPHX1KDM4ELMNARAB9AL3MBTL1
SCHEMBL3997055 0.68 AGXT (0.46) CYP1A2RAB9ANPC1
SCHEMBL27749471 0.68 PPARG (0.56) KDM4EALDH1A1CYP1A2CYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682484-A1 OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-26 EP disclosed
US-7081465-B2 Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-25 US disclosed
WO-2005042465-A1 OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2005-05-12 WO disclosed
US-20040192688-A1 Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192688-A1 Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders APOB, LIPC, FABP3 FAAH 67/4885EPHX1 1035/4885KDM4E 2830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.